Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.68 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.68 |
| ▸ | CCR3 | P51677 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.52 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4635628 | 1.00 | CHRM2 (0.68) | CHRM2CHRM3CCR3SIGMAR1OPRM1 | |
| SCHEMBL3075045 | 0.76 | CHRM2 (0.63) | CHRM2CHRM3CCR3SIGMAR1 | |
| SCHEMBL3075042 | 0.76 | CHRM2 (0.63) | CHRM2CHRM3CCR3SIGMAR1 | |
| SCHEMBL4634488 | 0.76 | SLC6A4 (0.75) | — | |
| SCHEMBL4634063 | 0.76 | SLC6A4 (0.75) | — | |
| Hydrochloric Acid SCHEMBL4634693 | 0.75 | SLC6A4 (0.73) | — | |
| Hydrochloric Acid SCHEMBL4635077 | 0.75 | SLC6A4 (0.73) | — | |
| SCHEMBL11461522 | 0.75 | CHRM2 (0.85) | CHRM2CHRM3SIGMAR1OPRM1 | |
| SCHEMBL4124844 | 0.75 | OPRM1 (0.70) | CHRM2CHRM3SIGMAR1OPRM1 | |
| SCHEMBL6414218 | 0.72 | CHRM2 (0.47) | CHRM2CHRM3OPRM1DRD4SLC6A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306123-A1 | NOVEL COMPOUNDS | PFIZER INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306123-A1 | NOVEL COMPOUNDS | PFIZER INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306123-A1 | NOVEL COMPOUNDS | PFIZER INC. (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1638933-B1 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2008-06-11 | — | — | EP | disclosed |
| EP-1638933-B1 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2008-06-11 | — | — | EP | disclosed |
| US-7378436-B2 | Compounds | PFIZER INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378436-B2 | Compounds | PFIZER INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378436-B2 | Compounds | PFIZER INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050137229-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | PFIZER INC | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137229-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | AOC3, ADRB3, HTR3C | CHRM2 139/4885CHRM3 69/4885CCR3 130/4885 |
| US-20080306123-A1 | NOVEL COMPOUNDS | ADRB3, HTR3A, HTR3C | CHRM2 53/4885CHRM3 38/4885CCR3 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.